Wünnemann et al.1515. Wünnemann F, Lo KS, Langford-Avelar A, Busseuil D, Dubé MP, Tardif JC, et al. Validation of Genome-wide Polygenic Risk Scores for Coronary Artery Disease in French Canadians. Circ Genom Precis Med. 2019;12(6):e002481. doi: 10.1161/CIRCGEN.119.002481. https://doi.org/10.1161/CIRCGEN.119.0024...
|
2019 |
Cohort |
North America |
11,021 |
Two PRS were effective in identifying French-Canadian individuals at high risk of developing CAD. |
Tikkanen et al.2323. Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S. Genetic Risk Prediction and a 2-Stage Risk Screening Strategy for Coronary Heart Disease. Arterioscler Thromb Vasc Biol. 2013;33(9):2261-6. doi: 10.1161/ATVBAHA.112.301120. https://doi.org/10.1161/ATVBAHA.112.3011...
|
2013 |
Cohort |
Europe |
24,124 |
Incorporating genetic information into risk assessment has enhanced the prevention and management of CAD. |
Khera et al.2424. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide Polygenic Scores for Common Diseases Identify Individuals with Risk Equivalent to Monogenic Mutations. Nat Genet. 2018;50(9):1219-24. doi: 10.1038/s41588-018-0183-z. https://doi.org/10.1038/s41588-018-0183-...
|
2018 |
Cohort |
Europe |
288,978 |
Individuals in the top 1% of the PRS distribution for over 6 million variants were nearly five times more likely to develop CAD. |
Inouye et al.2525. Inouye M, Abraham G, Nelson CP, Wood AM, Sweeting MJ, Dudbridge F, et al. Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults: Implications for Primary Prevention. J Am Coll Cardiol. 2018;72(16):1883-93. doi: 10.1016/j.jacc.2018.07.079. https://doi.org/10.1016/j.jacc.2018.07.0...
|
2018 |
Cohort |
Europe |
482,629 |
Genomic risk prediction can effectively identify individuals at a high risk of developing CAD. |
Lu et al.2626. Lu X, Liu Z, Cui Q, Liu F, Li J, Niu X, et al. A Polygenic Risk Score Improves Risk Stratification of Coronary Artery Disease: A Large-scale Prospective Chinese Cohort Study. Eur Heart J. 2022;43(18):1702-11. doi: 10.1093/eurheartj/ehac093. https://doi.org/10.1093/eurheartj/ehac09...
|
2022 |
Cohort |
China |
41,271 |
The use of a PRS significantly enhanced the identification of individuals at high risk of developing CAD in the Chinese population. |
Mega et al.2727. Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield M, Devlin JJ, et al. Genetic Risk, Coronary Heart Disease Events, and the Clinical Benefit of Statin Therapy: An Analysis of Primary and Secondary Prevention Trials. Lancet. 2015;385(9984):2264-71. doi: 10.1016/S0140-6736(14)61730-X. https://doi.org/10.1016/S0140-6736(14)61...
|
2015 |
Cohort |
Europe |
48,421 |
Individuals with a higher genetic predisposition to coronary events experienced a greater reduction in risk when treated with statins. |
Tada et al.2828. Tada H, Melander O, Louie JZ, Catanese JJ, Rowland CM, Devlin JJ, et al. Risk Prediction by Genetic Risk Scores for Coronary Heart Disease is Independent of Self-reported Family History. Eur Heart J. 2016;37(6):561-7. doi: 10.1093/eurheartj/ehv462. https://doi.org/10.1093/eurheartj/ehv462...
|
2021 |
Cohort |
Europe |
23,595 |
PRS can accurately assess CAD risk without considering family history, underscoring its utility as an independent risk prediction tool. |
Marston et al.2929. Marston NA, Pirruccello JP, Melloni GEM, Koyama S, Kamanu FK, Weng LC, et al. Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention. JAMA Cardiol. 2023;8(2):130-7. doi: 10.1001/jamacardio.2022.4466. https://doi.org/10.1001/jamacardio.2022....
|
2023 |
Cohort |
Europe |
330,201 |
The use of a PRS for CAD effectively predicted risk in primary prevention strategies. |
Natarajan et al.3030. Natarajan P, Young R, Stitziel NO, Padmanabhan S, Baber U, Mehran R, et al. Polygenic Risk Score Identifies Subgroup with Higher Burden of Atherosclerosis and Greater Relative Benefit from Statin Therapy in the Primary Prevention Setting. Circulation. 2017;135(22):2091-101. doi: 10.1161/CIRCULATIONAHA.116.024436. https://doi.org/10.1161/CIRCULATIONAHA.1...
|
2017 |
Cohort |
Europe |
4,392 |
The use of PRS identified a subgroup of individuals with a higher burden of atherosclerosis who may benefit most from statin therapy for primary prevention. |
Oni-Orisan et al.3131. Oni-Orisan A, Haldar T, Cayabyab MAS, Ranatunga DK, Hoffmann TJ, Iribarren C, et al. Polygenic Risk Score and Statin Relative Risk Reduction for Primary Prevention of Myocardial Infarction in a Real-world Population. Clin Pharmacol Ther. 2022;112(5):1070-8. doi: 10.1002/cpt.2715. https://doi.org/10.1002/cpt.2715...
|
2022 |
Cohort |
North America |
32,196 |
Individuals with a higher PRS experienced a more significant reduction in myocardial infarction risk with statin use compared to those with a lower PRS. |
Cornelissen et al.3232. Cornelissen A, Gadhoke NV, Ryan K, Hodonsky CJ, Mitchell R, Bihlmeyer NA, et al. Polygenic Risk Score Associates with Atherosclerotic Plaque Characteristics at Autopsy. Arterioscler Thromb Vasc Biol. 2024;44(1):300-13. doi: 10.1161/ATVBAHA.123.319818. https://doi.org/10.1161/ATVBAHA.123.3198...
|
2024 |
Cohort |
North America |
954 |
Individuals with a higher PRS tended to develop more extensive and complex atherosclerotic plaques, characterized by more unfavorable traits, including a greater propensity to rupture. |
Cho et al.3333. Cho SMJ, Koyama S, Honigberg MC, Surakka I, Haidermota S, Ganesh S, et al. Genetic, Sociodemographic, Lifestyle, and Clinical Risk Factors of Recurrent Coronary Artery Disease Events: A Population-based Cohort Study. Eur Heart J. 2023;44(36):3456-65. doi: 10.1093/eurheartj/ehad380. https://doi.org/10.1093/eurheartj/ehad38...
|
2023 |
Cohort |
Europe |
7,024 |
Genetic factors interacted with lifestyle and clinical factors, influencing the likelihood of recurrence of coronary events. |
Qin et al.3535. Qin M, Wu Y, Fang X, Pan C, Zhong S. Polygenic Risk Score Predicts All-cause Death in East Asian Patients with Prior Coronary Artery Disease. Front Cardiovasc Med. 2024;11:1296415. doi: 10.3389/fcvm.2024.1296415. https://doi.org/10.3389/fcvm.2024.129641...
|
2024 |
Cohort |
China |
1,776 |
Asian individuals with a higher PRS faced an increased risk of all-cause mortality. |
Howe et al.3636. Howe LJ, Dudbridge F, Schmidt AF, Finan C, Denaxas S, Asselbergs FW, et al. Polygenic Risk Scores for Coronary Artery Disease and Subsequent Event Risk Amongst Established Cases. Hum Mol Genet. 2020;29(8):1388-95. doi: 10.1093/hmg/ddaa052. https://doi.org/10.1093/hmg/ddaa052...
|
2020 |
Cohort |
Europe |
403,395 |
The PRS helped identify patients with established CAD who were most likely to experience additional events. |
Thompson et al.3737. Thompson PL, Hui J, Beilby J, Palmer LJ, Watts GF, West MJ, et al. Common Genetic Variants do Not Predict Recurrent Events in Coronary Heart Disease Patients. BMC Cardiovasc Disord. 2022;22(1):96. doi: 10.1186/s12872-022-02520-0. https://doi.org/10.1186/s12872-022-02520...
|
2022 |
Cohort |
Oceania |
4,932 |
Genetic variants did not significantly predict the occurrence of CAD after the disease was diagnosed. |
Kiflen et al.3838. Kiflen M, Le A, Mao S, Lali R, Narula S, Xie F, et al. Cost-effectiveness of Polygenic Risk Scores to Guide Statin Therapy for Cardiovascular Disease Prevention. Circ Genom Precis Med. 2022;15(5):e003423. doi: 10.1161/CIRCGEN.121.003423. https://doi.org/10.1161/CIRCGEN.121.0034...
|
2022 |
Cost-effectiveness |
Europe |
96,116 |
Using PRS to guide statin therapy was cost-effective compared to strategies based solely on traditional risk factors. |
Mujwara et al.3939. Mujwara D, Kintzle J, Di Domenico P, Busby GB, Bottà G. Cost-effectiveness Analysis of Implementing Polygenic Risk Score in a Workplace Cardiovascular Disease Prevention Program. Front Public Health. 2023;11:1139496. doi: 10.3389/fpubh.2023.1139496. https://doi.org/10.3389/fpubh.2023.11394...
|
2023 |
Cost-effectiveness |
North America |
47,108 |
Implementing PRS in a workplace prevention program proved to be cost-effective. |
Mujwara et al.4040. Mujwara D, Henno G, Vernon ST, Peng S, Di Domenico P, Schroeder B, et al. Integrating a Polygenic Risk Score for Coronary Artery Disease as a Risk-enhancing Factor in the Pooled Cohort Equation: A Cost-effectiveness Analysis Study. J Am Heart Assoc. 2022;11(12):e025236. doi: 10.1161/JAHA.121.025236. https://doi.org/10.1161/JAHA.121.025236...
|
2022 |
Cost-effectiveness |
North America |
47,108 |
Integrating PRS as an additional risk factor into pooled cohort equations enhanced the accuracy of CAD risk stratification while remaining cost-effective. |